Chronic Cancer Pain
Screening for pain at every visit is recommended, and management and treatment options are specified.
The term "contract" when used in regard to agreements with patients who have chronic pain is dated, perceived negatively and not preferred.
Fentanyl nasal spray is indicated for breakthrough pain in opioid-tolerant patients who are already receiving and tolerant to continuous opioid therapy for underlying persistent cancer pain.
Variability in baseline breakthrough pain (BTP) has no impact on the analgesic response to sublingual fentanyl tablets or placebo.